$EDSA: @EdesaBiotech – Positive Interim Efficacy Analysis For EB01 Phase 2b Trial In Allergic Contact Dermatitis… – https://t.co/DUnY5VckGv by @DavidBautz pic.twitter.com/k3t8EizaRZ
— Zacks SCR (@ZacksSmallCap) June 4, 2021
SVB Leerink Maintains Market Perform on Elevation Oncology, Lowers Price Target to $1
SVB Leerink analyst Andrew Berens maintains Elevation Oncology (NASDAQ:ELEV) with a Market Perform and lowers the price target from $2 to $1.
